The Latin America, Middle East and Africa Arteriovenous Fistula Devices Market would witness market growth of 11.2% CAGR during the forecast period (2023-2030).
Arteriovenous malformations (AVM), also known as AVF, are currently being treated by endovascular embolization. A catheter is inserted via the groin into the brain arteries that contributes to the AVM during this treatment, and a substance is injected into the arteries. The artery is blocked by this injection, which reduces blood supply to the AVM. Endovascular embolization is nearly always employed as a first step in either microsurgical excision or stereotactic radiotherapy preparation since it typically does not eliminate the AVM on its own.
Businesses involved in the market are now more involved with launching strategies like corporate social responsibility (CSR) programs, targeted marketing, etc. Additionally, the rising efforts to increase awareness of the availability of such devices because AVF devices offer many benefits. Since there is no foreign material present, unlike a catheter implanted for dialysis, which can provide a direct channel for infection to reach the body, infection rates are lower. For the best dialysis sessions, higher blood flow rates can be provided by AVFs. It also results in fewer instances of clot formation or thrombosis.
According to research looking at the prevalence of CKD, diabetes mellitus has become the primary risk factor for CKD in this region. The Saudi Medical Journal reports that between 2002 and 2018, a different study evaluated the prevalence of type 2 diabetes mellitus (T2DM) among females in Arab nations. Belize has seen the biggest increase (10 percentage points), whereas the incidence in Venezuela and Uruguay fell by about 6 percentage points between 2010 and 2019. Therefore, the rising prevalence of diabetes mellitus will lead to an increase in kidney disease, thereby propelling the expansion of the market.
The Brazil market dominated the LAMEA Arteriovenous Fistula Devices Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $10.4 million by 2030. The Argentina market is poised to grow at a CAGR of 11.8% during (2023 - 2030). Additionally, The UAE market would exhibit a CAGR of 10.9% during (2023 - 2030).
Based on End-use, the market is segmented into Hospitals, Ambulatory Surgical Centers and Dialysis Centers. Based on Type, the market is segmented into AVF Creation Devices (Surgical Instruments, Vascular Grafts, Angioplasty Balloons and Others), AVF Monitoring Devices (Doppler Ultrasound, Pressure Monitoring Systems, and Others) and AVF Maintenance Devices (Central Venous Catheters, Stents and Others). Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
Free Valuable Insights: The Worldwide Arteriovenous Fistula Devices Market is Projected to reach USD 521.9 Million by 2030, at a CAGR of 6.9%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Medtronic PLC, Becton, Dickinson and Company, Teleflex, Inc., Fresenius Medical Care AG & Co. KGaA. (Fresenius SE & Co. KGaA), B. Braun Melsungen AG, Poly Medicure Ltd., Asahi Kasei Corporation, Laminate Medical Technologies Ltd., Cook Medical, Inc. (Cook Group), and Boston Scientific Corporation
By End-use
By Type
By Country
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
